Background and Aims. Since the war in Ukraine which began on February 2022, many pediatric oncology centers have welcomed patients from Ukraine. To understand the needs of patients and families arriving at our hospital, an anonymous questionnaire investigated the families’ backgrounds, feelings and impressions about hospitality and care. Methods Twenty items investigated how patients had reached Italy, from whom they received help (logistically/economically); emotions regarding their statusas war refugees; knowledge, expectations, and opinions about Italy and Italians; the quality of medical care received and relationships with the healthcare staff; suggestions to improve assistance. Results Questionnaires were completed by 19/32 patient/parents in the time interval May-November 2022 in two different pediatric-oncology centers in the north of Italy. Most families had reached Italy (58%) and received medical care (95%) thanks to the help of Charities and the Italian Public Health Care System. Many of them (69%) declared themselves to be satisfied by the assistance. The Italian population appeared friendly (95%) and generous (58%). The improvement of their stay correlated with the positive outcome of their children (15%), the presence of the whole family (15%), the end of the war (10%), and the overcoming of language barriers (10%) Conclusions. Taking care of children from a different country suffering the traumatic experience of fleeing their country in addition to the equally traumatic condition of cancer disease, is a huge task. Our questionnaire aimed at obtaining a better understanding of families’ conditions, not at bridging the relational gap due to different culture and experiences.

During SARS-CoV-2 pandemic, oncologists manage patients at higher risk of having a severe course of this infection. This raises new questions about their correct management, as well as the difficulty of distinguishing tumor/treatments complications from those related to Coronavirus disease 2019 (COVID-19). We report a case of an 11 year-old boy undergoing treatment for T cell lymphoblastic lymphoma who experienced a prolonged SARS-CoV-2 infection. Oncological therapy was continued without significant changes compared to the initially planned treatment. No relevant complications occurred. COVID-19 convalescent plasma (CP) was administered, resulting in a positive antibody titer after 24 days.

Introduction. Mutations of the APC (adenomatous polyposis coli) gene correlate mainly with familial adenomatous polyposis (FAP), but can occasionally be pathogenic for medulloblastoma (MBL) WNT subtype as well, the course of which has only recently been described. Methods. We retrospectively retrieved all patients with documented germline APC mutations and a centrally-reviewed diagnosis of MBL to examine the outcome of their MBL, late effects of its treatment, and further oncological events. Results. Between 2007-2016 we diagnosed and treated 6 patients, all with a pathogenic APC variant mutation, who all had MBL, classic histotype. None had metastatic disease. All patients were in complete remission a median 65 months after treatment with craniospinal irradiation at 23.4 Gy, plus a boost on the posterior fossa/tumor bed up to 54 Gy, followed by cisplatin/carboplatin, lomustine and vincristine for a maximum of 8 courses. Five of 6 diagnostic revised MRI were suggestive of the WNT molecular subgroup typical aspects. Four of 6 patients had a positive family history of FAP, while gastrointestinal symptoms prompted its identification in the other 2 cases. Four patients had developed other tumors (desmoid, MELTUMP, melanoma, pancreatoblastoma, thyroid Tir3) from 5 to 7 years after MBL. Discussion. Our data confirm a good prognosis for patients with MBL associated with FAP. Patients’ secondary tumors may or may not be related to their syndrome or treatment, but warrant adequate attention when planning shared guidelines for these patients.

We analyzed the nationwide hospital discharge records of adolescent inpatients in Italy to map where adolescents with melanoma are treated and identify expert centers. We identified 137 hospitals pointing out a dispersion of these patients that must be addressed to ensure to all adolescents with melanoma adequate treatment and enrolment in clinical studies.